|
1
|
Chen YL, Huang ZQ, Zhou NX, Zhang WZ,
Huang XQ, Duan WD, Liu R and Liu Y: Clinical analysis of 110
patients with primary gallbladder carcinoma. Zhonghua Zhong Liu Za
Zhi. 29:704–706. 2007.(In Chinese). PubMed/NCBI
|
|
2
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ashkenazi A: Targeting the extrinsic
apoptosis pathway in cancer. Cytokine Growth Factor Rev.
19:325–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Korkolopoulou P, Saetta AA, Levidou G,
Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K,
Michalopoulos NV, Apostolikas N, et al: c-FLIP expression in
colorectal carcinomas: Association with Fas/FasL expression and
prognostic implications. Histopathology. 51:150–156. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, Li W and Olumi AF: Overcoming
resistance to trail-induced apoptosis in prostate cancer by
regulation of c-FLIP. Methods Enzymol. 446:333–349. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haag C, Stadel D, Zhou S, Bachem MG,
Moller P, Debatin KM and Fulda S: Identification of c-FLIP(L) and
c-FLIP(S) as critical regulators of death receptor-induced
apoptosis in pancreatic cancer cells. Gut. 60:225–237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tian F, Lu JJ, Wang L, Li L, Yang J, Li Y,
Liu YQ, Shen GX, Tu YT and Tao J: Expression of c-FLIP in malignant
melanoma, and its relationship with the clinicopathological
features of the disease. Clin Exp Dermatol. 37:259–265. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zong H, Yin B, Chen J, Ma B, Cai D and He
X: Over-expression of c-FLIP confers the resistance to
TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med.
217:203–208. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shirley S and Micheau O: Targeting c-FLIP
in cancer. Cancer Lett. 332:141–150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen F, Zhu HH, Zhou LF, Wu SS, Wang J and
Chen Z: Inhibition of c-FLIP expression by miR-512-3p contributes
to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol
Rep. 23:1457–1462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jia K, Shi P, Han X, Chen T, Tang H and
Wang J: Diagnostic value of miR-30d-5p and miR-125b-5p in acute
myocardial infarction. Mol Med Rep. 14:184–194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang XL, Zhao YY, Sun L, Shi Y, Li ZQ,
Zhao XD, Xu CG, Ji HG, Wang M, Xu WR and Zhu W: Exosomes derived
from human umbilical cord mesenchymal stem cells improve myocardial
repair via upregulation of Smad7. Int J Mol Med. 41:3063–3072.
2018.PubMed/NCBI
|
|
15
|
Benoist S, Panis Y and Fagniez PL:
Long-term results after curative resection for carcinoma of the
gallbladder. French University Association for Surgical Research.
Am J Surg. 175:118–122. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gourgiotis S, Kocher HM, Solaini L,
Yarollahi A, Tsiambas E and Salemis NS: Gallbladder cancer. Am J
Surg. 196:252–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Misra S, Chaturvedi A, Misra NC and Sharma
ID: Carcinoma of the gallbladder. Lancet Oncol. 4:167–176. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saetta AA: K-ras, p53 mutations, and
microsatellite instability (MSI) in gallbladder cancer. J Surg
Oncol. 93:644–649. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takagawa M, Muguruma N, Oguri K, Imoto Y,
Okamoto K, Ii K and Ito S: Prediction of prognosis in gallbladder
carcinoma by mucin and p53 immunohistochemistry. Dig Dis Sci.
50:1410–1413. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masuhara S, Kasuya K, Aoki T, Yoshimatsu
A, Tsuchida A and Koyanagi Y: Relation between K-ras codon 12
mutation and p53 protein overexpression in gallbladder cancer and
biliary ductal epithelia in patients with pancreaticobiliary
maljunction. J Hepatobiliary Pancreat Surg. 7:198–205. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang BL, Zhai HY, Chen BY, Zhai SP, Yang
HY, Chen XP, Zhao WT and Meng L: Clinical relationship between MDR1
gene and gallbladder cancer. Hepatobiliary Pancreat Dis Int.
3:296–299. 2004.PubMed/NCBI
|
|
22
|
Meyerhardt JA, Zhu AX, Stuart K, Ryan DP,
Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P and Fuchs
CS: Phase-II study of gemcitabine and cisplatin in patients with
metastatic biliary and gallbladder cancer. Dig Dis Sci. 53:564–570.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iyer RV, Gibbs J, Kuvshinoff B, Fakih M,
Kepner J, Soehnlein N, Lawrence D and Javle MM: A phase II study of
gemcitabine and capecitabine in advanced cholangiocarcinoma and
carcinoma of the gallbladder: A single-institution prospective
study. Ann Surg Oncol. 14:3202–3209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong YS, Lee J, Lee SC, Hwang IG, Choi SH,
Heo JS, Park JO, Park YS, Lim HY and Kang WK: Phase II study of
capecitabine and cisplatin in previously untreated advanced biliary
tract cancer. Cancer Chemother Pharmacol. 60:321–328. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Jin TG, Yang H, DeWolf WC,
Khosravi-Far R and Olumi AF: Persistent c-FLIP(L) expression is
necessary and sufficient to maintain resistance to tumor necrosis
factor-related apoptosis-inducing ligand-mediated apoptosis in
prostate cancer. Cancer Res. 64:7086–7091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Safa AR: c-FLIP, a master anti-apoptotic
regulator. Exp Oncol. 34:176–184. 2012.PubMed/NCBI
|
|
28
|
McCourt C, Maxwell P, Mazzucchelli R,
Montironi R, Scarpelli M, Salto-Tellez M, O'Sullivan JM, Longley DB
and Waugh DJ: Elevation of c-FLIP in castrate-resistant prostate
cancer antagonizes therapeutic response to androgen
receptor-targeted therapy. Clin Cancer Res. 18:3822–3833. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geserick P, Drewniok C, Hupe M, Haas TL,
Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H,
Walczak H and Leverkus M: Suppression of cFLIP is sufficient to
sensitize human melanoma cells to TRAIL-and CD95L-mediated
apoptosis. Oncogene. 27:3211–3220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White SJ, Lu P, Keller GM and
Voelkel-Johnson C: Targeting the short form of cFLIP by RNA
interference is sufficient to enhance TRAIL sensitivity in PC3
prostate carcinoma cells. Cancer Biol Ther. 5:1618–1623. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du X, Bao G, He X, Zhao H, Yu F, Qiao Q,
Lu J and Ma Q: Expression and biological significance of c-FLIP in
human hepatocellular carcinomas. J Exp Clin Cancer Res. 28:242009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Longley DB, Wilson TR, McEwan M, Allen WL,
McDermott U, Galligan L and Johnston PG: c-FLIP inhibits
chemotherapy-induced colorectal cancer cell death. Oncogene.
25:838–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo A, Wang W, Sima N, Lu Y, Zhou J, Xu G,
Yu H, Wang S and Ma D: Short hairpin RNA targeting c-FLIP
sensitizes human cervical adenocarcinoma Hela cells to chemotherapy
and radiotherapy. Cancer Lett. 271:323–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: Bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun YM, Lin KY and Chen YQ: Diverse
functions of miR-125 family in different cell contexts. J Hematol
Oncol. 6:62013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu
N, Fu Z and You Y: MiR-125b is critical for the suppression of
human U251 glioma stem cell proliferation. Brain Res. 1312:120–126.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu
J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic
implications of microRNAs in human hepatocellular carcinoma. Int J
Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nishida N, Yokobori T, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H and Mori M: MicroRNA
miR-125b is a prognostic marker in human colorectal cancer. Int J
Oncol. 38:1437–1443. 2011.PubMed/NCBI
|
|
41
|
Yamada A, Horimatsu T, Okugawa Y, Nishida
N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, et al: Serum
miR-21, miR-29a, and miR-125b are promising biomarkers for the
early detection of colorectal neoplasia. Clin Cancer Res.
21:4234–4242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim SW, Ramasamy K, Bouamar H, Lin AP,
Jiang D and Aguiar RC: MicroRNAs miR-125a and miR-125b
constitutively activate the NF-KB pathway by targeting the tumor
necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl
Acad Sci USA. 109:7865–7870. 2012. View Article : Google Scholar : PubMed/NCBI
|
